Prognostic value of fasting glucose on the risk of heart failure and left ventricular systolic dysfunction in non-diabetic patients with ST-segment elevation myocardial infarction

• Published in: Frontiers of medicine Vol. 15; no. 1; pp. 70 - 78
• Main Authors: Wang, Hui, Zhang, Yang, Shen, Zhujun, Fang, Ligang, Liu, Zhenyu, Zhang, Shuyang
• Format: Journal Article
• Language: English
• Published: Beijing Higher Education Press 01.02.2021; Springer Nature B.V
• Subjects: Aged; Diabetes; diabetes mellitus; Fasting; fasting glucose; Female; Glucose; Heart attacks; Heart Failure; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; myocardial infarction; Percutaneous Coronary Intervention; Prognosis; Research Article; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction - surgery; heart failure; percutaneous coronary intervention; diabetes mellitus; fasting glucose; myocardial infarction
• ISSN: 2095-0217; 2095-0225
• DOI: 10.1007/s11684-020-0749-x

Recent studies have shown that acute blood glucose elevation in patients with ST-segment elevation myocardial infarction (STEMI) suggests a poor prognosis. To investigate the effect of fasting blood glucose (FBG) on the risk of heart failure (HF) and left ventricular systolic dysfunction (LVSD) in non-diabetic patients undergoing primary percutaneous coronary intervention (PCI) for acute STEMI, we retrospectively recruited consecutive non-diabetic patients who underwent primary PCI for STEMI in our hospital from February 2003 to March 2015. The patients were divided into two groups according to the FBG level. A total of 623 patients were recruited with an age of 61.3±12.9 years, of whom 514 (82.5%) were male. The HF risk (odds ratio 3.401, 95% confidence interval (CI) 2.144-5.395, P <0.001) was significantly increased in patients with elevated FBG than those with normal FBG. Elevated FBG was also independently related to LVSD (β 1.513, 95%CI 1.282-1.785, P <0.001) in a multiple logistics regression analysis. In conclusion, elevated FBG was independently associated with 30-day HF and LVSD risk in non-diabetic patients undergoing primary PCI for STEMI.